Meeting
2017 Genitourinary Cancers Symposium
Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.
Authors
Manish R. Patel
Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL
Manish R. Patel , John Allan Ellerton , Jeffrey R. Infante , Manish Agrawal , Michael S. Gordon , Raid Aljumaliy , Carolyn D. Britten , Luc Dirix , Keun-Wook Lee , Matthew H. Taylor , Patrick Schöffski , Ding Wang , Alain Ravaud , Arnold Gelb , Junyuan Xiong , Galit Rosen , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 330)
DOI
10.1200/JCO.2017.35.6_suppl.330
Abstract #
330
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
First Author: Andrea B. Apolo
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
First Author: Andrea B. Apolo
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.
First Author: Mary L. Disis
Poster
2016 Genitourinary Cancers Symposium
Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
First Author: Andrea B. Apolo